IGF2BP1 and colonic neoplasm: It was found that the expression of IGF2BP1 (probe: 227377_at*) was not altered in non-responders to any chemotherapy (5-fluorouracil, oxaliplatin, bevacizumab, irinotecan, and capecitabine) compared to 91 responder colon cancer patients (Figure 3A).